Galderma Group AGXSWX:GALD -2.75%15 PB Ratio is 6.45 as of Jun. 26, 2026, which is 52% above its 10-year median of 4.23. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Galderma Group AG ranks worse than 88.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Galderma Group AG's share price is CHF178.50. Galderma Group AG's Book Value per Share for the quarter that ended in Dec. 2025 was CHF27.69. Hence, Galderma Group AG's PB Ratio of today is 6.45.
Warning Sign:
Galderma Group AG stock PB Ratio (=6.23) is close to 3-year high of 6.23.
The historical rank and industry rank for Galderma Group AG's PB Ratio or its related term are showing as below:
XSWX:GALD'
s PB Ratio Range Over the Past 10 Years
Min: 2.6 Med: 4.23 Max: 6.64
Current: 6.46
During the past 5 years, Galderma Group AG's highest PB Ratio was 6.64. The lowest was 2.60. And the median was 4.23.
XSWX:GALD's PB Ratio is ranked worse than 88.07% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs XSWX:GALD: 6.46
During the past 12 months, Galderma Group AG's average Book Value Per Share Growth Rate was -5.40% per year.
Back to Basics: PB Ratio
Galderma Group AG (XSWX:GALD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Galderma Group AG PB Ratio Related Terms
Galderma Group AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Galderma Group AG (XSWX:GALD) has a PB Ratio of 6.45 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Galderma Group AG and its competitors. This is 52% above median its historical median of 4.23. Over the past decade, Galderma Group AG's PB Ratio has ranged from 2.60 to 6.64. According to the industry distribution chart, Galderma Group AG ranks #812 out of 922 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Galderma Group AG's PB Ratio too high?
Galderma Group AG's current PB Ratio of 6.45 is 52% above median its 10-year median of 4.23. Over the past 10 years, this metric has ranged from a low of 2.60 to a high of 6.64. The Drug Manufacturers industry median PB Ratio is 1.83. Galderma Group AG's value of 6.45 is 253.4% above this industry median. Based on the distribution chart, Galderma Group AG ranks #812 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #812 out of 922 companies for PB Ratio. This places Galderma Group AG in the lower half of its industry. The industry median PB Ratio is 1.83. Galderma Group AG's value of 6.45 is 253.4% above this benchmark. Historically, Galderma Group AG's own PB Ratio has ranged from 2.60 to 6.64 over the past decade. While the company's 10-year median is 4.23 vs. the industry median of 1.83, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current PB Ratio of 6.45 is 253.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current PB Ratio is 6.45, which is 52% above median its own 10-year median of 4.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current PB Ratio of 6.45. The current PB Ratio is 6.45, which is 52% above median its 10-year median of 4.23 and 253.4% above the Drug Manufacturers industry median of 1.83. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current PB Ratio is 6.45 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 